Thu, Dec 18, 2014, 7:49 AM EST - U.S. Markets open in 1 hr 41 mins

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • richrd_cc richrd_cc Jul 23, 2014 10:11 AM Flag

    Phase III - Futility Analysis

    Another big piece in the news release yesterday was that the Phase III study will include an interim futility analysis. Futility analyses are usually used to evaluate one of two things:

    1. Has the product continued with extraordinary positive performance. This is performed with hopes of stopping the trial early to advance approval.
    2. Is the product performing as poor as expected based upon Phase II results. This futility analysis is added with low expectations with intentions of terminating the trial.

    Ganetespib was depicted as having very positive results in Phase II and was moved into Phase III. The news indicates to me that this interim futility analysis is for the former reason.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SNTA
2.72+0.0600(+2.26%)Dec 17 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.